Articles from Brixton Biosciences

Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced that data from the Company’s pivotal NICE clinical trial evaluating Reneurx™ Nerve-Selective Therapy for pain associated with knee osteoarthritis will be presented during a podium presentation at the Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS), hosted November 5-8 in Dallas, Texas.

Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointments of David Acheson as Chief Commercial Officer and Brian Newkirk as Chief Business Officer. The appointments strengthen Brixton's executive leadership team as the Company prepares for potential commercialization of its lead product, Reneurx™ Nerve-Selective Therapy for pain associated with knee osteoarthritis, with additional clinical and research initiatives focused on lateral hip pain, thumb joint pain and migraine.

Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Brand. The appointments come as Brixton prepares for U.S. Food and Drug Administration (FDA) marketing authorization and commercialization of its lead investigational product, Reneurx™ Nerve-Selective Therapy.